uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
19 déc. 2023 07h05 HE
|
uniQure Inc.
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...
Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon, SOM, Vaccinex, Sage, UniQure, Wave life sciences, Takeda, Medesis
01 nov. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon,...
Digital Brain Health Market Predicted to Reach US$ 382.9 billion by 2031, Growing at a 7.3% CAGR Says, Transparency Market Research
26 oct. 2023 04h33 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The digital brain health market was valued at US$ 184.7 billion in 2021. The market is...
Hereditary Disease Foundation Announces Recipients of Inaugural Transformative Research Award
04 oct. 2023 14h38 HE
|
Hereditary Disease Foundation
New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation has announced that the recipients of its first Transformative Research Awards are two teams - one led by Beverly...
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
26 sept. 2023 08h00 HE
|
Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
21 juin 2023 07h05 HE
|
uniQure Inc.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural...
Rumi Scientific Announces Data Demonstrating Disease Modifying Effect of BRD9 Inhibition in a Huntington’s Disease Animal Model
26 avr. 2023 07h05 HE
|
Rumi Scientific, Inc.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of Directors
30 mars 2023 08h00 HE
|
Rumi Scientific, Inc.
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
22 mars 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended...
Hereditary Disease Foundation Announces 2022 Prize Winners for Leadership in Huntington’s Disease Research
19 oct. 2022 11h02 HE
|
Hereditary Disease Foundation
New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation today announced the winners of its 2022 prizes for leadership in Huntington’s disease research. -- Steven...